ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

Shares of Resmed Inc. (RMD) traded over 7% higher in pre-market on Thursday morning after the company’s third-quarter ...

ResMed Inc (RMD) reports an 8% revenue increase and plans to boost share buybacks, while navigating global trade challenges ...

ResMed (ASX:RMD) has reported it received an exemption from the current U.S. Administration, meaning it can keep sending its ...

Respiratory health company ResMed has posted strong revenue growth and double-digit earnings increase in the third quarter, ...

Chief executive Mick Farrell says he’s confident the medical device company’s exports from Australia and Singapore will not ...

Morgans senior healthcare analyst Scott Power says healthcare stocks have had a strong start to the latest reporting season.

ResMed Inc. (ASX: RMD) shares are having a strong finish to the week. Here's why investors are buying this blue chip ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Analysts have provided ResMed with 5 ratings, resulting in a consensus rating of Outperform. The average one-year price ...

Resmed has named Salli Schwartz as chief investor relations officer, where she will lead the company’s global investor relations function and report to Mick Farrell, chairman of the board ...

Revenue Growth: Over the 3M period, ResMed showcased positive performance, achieving a revenue growth rate of 10.26% as of 31 December, 2024. This reflects a substantial increase in the company's ...